aTyr Pharma (ATYR) Expected to Announce Quarterly Earnings on Thursday

aTyr Pharma (NASDAQ:ATYR) will likely be announcing its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $0.02 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 17, 2026 at 4:00 PM ET.

aTyr Pharma Trading Up 0.5%

Shares of aTyr Pharma stock opened at $0.96 on Thursday. The stock has a market capitalization of $94.51 million, a price-to-earnings ratio of -1.16 and a beta of 0.55. aTyr Pharma has a 1-year low of $0.64 and a 1-year high of $7.29. The firm’s 50-day moving average price is $0.83 and its two-hundred day moving average price is $1.47.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of aTyr Pharma in a report on Monday, December 29th. One analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $25.67.

Hedge Funds Weigh In On aTyr Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Millennium Management LLC lifted its position in aTyr Pharma by 334.5% during the 1st quarter. Millennium Management LLC now owns 1,599,041 shares of the company’s stock worth $4,829,000 after buying an additional 1,231,052 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of aTyr Pharma by 46.0% in the first quarter. Goldman Sachs Group Inc. now owns 382,317 shares of the company’s stock valued at $1,155,000 after acquiring an additional 120,496 shares during the last quarter. Creative Planning bought a new stake in aTyr Pharma during the second quarter worth about $74,000. JPMorgan Chase & Co. bought a new stake in aTyr Pharma during the second quarter worth about $208,000. Finally, Legal & General Group Plc acquired a new position in aTyr Pharma during the second quarter valued at approximately $49,000. 61.72% of the stock is owned by institutional investors and hedge funds.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.